Client news

A&O Shearman advises D. Boral Capital LLC on USD22 million registered direct offering of Omeros Corporation

A&O Shearman advises D. Boral Capital LLC on USD22 million registered direct offering of Omeros Corporation
Published Date
Aug 11 2025
A&O Shearman advised D. Boral Capital LLC as the exclusive placement agent on USD22m registered direct offering of Omeros Corporation, pursuant to which Omeros sold 5,365,853 shares of its common stock at a purchase price of USD4.10 per share.
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders.

“We are proud to be able to support D. Boral Capital in its work with a company as dynamic and pathbreaking as Omeros,”

“We are proud to be able to support D. Boral Capital in its work with a company as dynamic and pathbreaking as Omeros,” said capital markets partner Yian Huang. “This transaction demonstrates the ability of our capital markets practice to deliver constructive advice to financial institutions and companies in the healthcare sector.”

The A&O Shearman team was led by capital markets partners Yian Huang and Chris Forrester, supported by senior associate David Lee and associate Leilani Lu. Partner Jennifer Morton and senior associate Taylor Pugliese advised on FINRA-related aspects.

Related capabilities